GeneChem is a manager of focused venture capital funds. Since 1997, we have been involved in the launching of companies and in the management of their growth and liquidity events.

GeneChem has been part of investment syndicates which included a wide breadth of marquee international investors as well as smaller local players. The team has knowledge and expertise in various fields of science including biochemistry, chemistry, immunology, oncology, virology, bacteriology, analgesia, ophthalmology and human genetics.

We have invested at the very early stages of start-ups, where hands-on management is required, and also at the later stages such as mezzanine rounds and private placements in public entities. The team's experience is broad and deep-reaching within the biotech investment sector.

1 Westmount Square, Suite 800
Montreal, Quebec
H3Z 2P9

T 514-849-7696
F 514-849-5191

Élizabeth Douville, PhD General Partner

Dr. Douville joined GeneChem in 1997 as a Manager of the Technologies Fund and was promoted to Vice President in 2001 with the raising of their Therapeutics Fund.  In 2006, Dr. Douville became General Partner with the raising of their third fund, AgeChem.  As of January 2011, Dr. Douville is co-managing the fourth and latest venture fund, AmorChem. 

Dr. Douville is an active board member of Alethia Biotherapeutics and she was an active member of the boards of directors of Cytochroma Inc., Ambit Biosciences Inc., LymphoSign Inc. and Chronogen Inc. and was also a board member of Idun Pharmaceuticals Inc. before its sale to Pfizer in 2005.  Elizabeth obtained her Ph.D. in biochemistry at the University of Ottawa (1994), studying the role of protein tyrosine kinases in oncogenesis. She then received postdoctoral training at the Imperial Cancer Research Fund in London (U.K.) from 1994 to 1997 where she studied oncogenes and their signal transduction pathways.  In 2008, Elizabeth obtained a business certificate degree as part of the “Programme de perfectionnement des cadres supérieurs” (an Executive management and training program) offered by CIREM in collaboration with HEC/University of Montreal.

T 514-849-6358
F 514-849-5191



HomeAbout UsGeneChem TechGeneChem TheraAgeChemAmorChemNuChemOur TeamContact UsFrançais

© 2024 GeneChem. All rights reserved. Developed by Grafika Designs a Montreal Web Design company.